This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Clovis Oncology’s CO-1686 Continues To Demonstrate Promising Clinical Activity And Safety In Updated Phase I Study Results

The Phase I dose escalation portion of the study is being conducted in the United States, France and Australia in patients with metastatic or unresectable recurrent NSCLC and a documented EGFR mutation. Patients were not required to be T790M positive for the Phase I portion of the study but had to have progressed on prior EGFR-directed tyrosine kinase inhibitor (TKI) therapy (prior chemotherapy was also allowed).

Evidence of Activity

As of October 2013, nineteen patients have been treated in the 900mg BID cohort. Of those nineteen patients, five were T790M negative and fourteen were T790M positive (five non-evaluable).

In the nine evaluable T790M positive patients, a 67 percent overall response rate was demonstrated. Six patients achieved RECIST partial responses and two patients achieved tumor shrinkage of 10-20 percent. Patients were heavily pretreated prior to receiving CO-1686; eight of the nine patients had immediately progressed on a TKI prior to treatment. Six of the nine patients received two or more previous TKI lines. As expected, no objective responses were seen in T790M negative patients.

Previously, the Company reported data at ASCO for a total of four evaluable T790M positive patients treated in the 900mg BID cohort; one patient with stable disease and three patients with PRs. Additionally, the Company reported one patient with a PR from the 300mg BID cohort. Of the four patients with PRs, three of the four remain on drug. Two patients have maintained their responses and one patient remains on drug despite having formally progressed. The median progression free survival time for these four responding patients has not yet been reached but is greater than 181 days.

Safety and Tolerability

CO-1686 appears to be well-tolerated with no evidence of rash or dose-related diarrhea. There are limited and low-grade adverse events in patients to date. The most common adverse events attributed to CO-1686 therapy include nausea (21%), diarrhea (20%), fatigue (20%), vomiting (13%) and decreased appetite (11%). These did not lead to study drug discontinuation.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs